Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment
Study Details
Study Description
Brief Summary
Extracorporeal Photopheresis (ECP) is a form of apheresis and photodynamic therapy in which the peripheral blood is treated with 8-methoxypsoralen, which is then activated with UV light. ECP is currently a standard therapy for cutaneous T-cell lymphoma (CTCL) and is also effective for graft-versus-host disease (GVHD). The investigators would like to study the outcomes (response rates) of patients receiving ECP treatment and other factors relating to their disease and treatment, as well as procedural events, such as complications.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
The investigators intend to report outcomes from the inception of this procedure at Dartmouth-Hitchcock Medical Center (DHMC) in May 2008 through 9/30/11. Additionally, the investigators would like to maintain a prospective database of these patients so that new patient data can be collected for updating of outcomes.
Study Design
Outcome Measures
Primary Outcome Measures
- Response rates [1 year]
Response rates to ECP treatment
Secondary Outcome Measures
- Complications [1 year]
Complications to ECP procedures
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients who receive Extracorporeal Photopheresis treatment
-
Treated at Dartmouth-Hitchcock Medical Center
-
Must be 18 years or older
Exclusion Criteria:
- None specified
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | United States | 03756 |
Sponsors and Collaborators
- Dartmouth-Hitchcock Medical Center
Investigators
- Principal Investigator: Frederick Lansigan, MD, Dartmouth-Hitchcock Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- D11271